Status:
COMPLETED
Circulating Tumor Cells in Non-Small Cell Lung Carcinoma
Lead Sponsor:
Epic Sciences
Collaborating Sponsors:
Yale University
Billings Clinic
Conditions:
Primary Lung Cancer
Eligibility:
All Genders
19+ years
Brief Summary
The purpose of this study is to establish the circulating tumor cell (CTC) assay as a surrogate for tissue diagnosis of suspected primary lung cancer. This is done through evaluating clinical and mole...
Eligibility Criteria
Inclusion
- Suspected lung cancer
- Planned to undergo tissue biopsy. Tissue biopsy does not need to be limited to an intrathoracic structures. Biopsies of the supraclavicular lymph nodes are allowed
- Age \>18
Exclusion
- Patients with history of a separate (not a primary lung cancer) malignancy within past two years.
- Recent history (past two weeks) of trauma (INCLUDING diagnostic surgery, biopsy, etc)
- Prior lung cancer treatment chemotherapy, radiation, surgery, etc. in past two years.
- Inability to provide informed consent.
- Hgb less than 8.
Key Trial Info
Start Date :
November 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
232 Patients enrolled
Trial Details
Trial ID
NCT01830426
Start Date
November 1 2012
End Date
January 1 2016
Last Update
January 22 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Moores Cancer Center
La Jolla, California, United States, 92093
2
Yale University
New Haven, Connecticut, United States, 06510
3
Billings Clinic Cancer Center
Billings, Montana, United States, 59101